GlassScriptPhysician profile
John J Jolley
NPI 1760590269
$6,669.13
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $729 · 2021: $2,809 · 2022: $2,213 · 2023: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $384.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,306.14 | 2019-2023 | Xifaxan |
| Janssen Biotech, INC. | $1,102.00 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $926.38 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $855.82 | 2019-2023 | Entyvio |
| Abbvie INC. | $479.12 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $279.49 | 2021-2023 | Linzess |
| Celgene Corporation | $230.96 | 2021-2022 | |
| Redhill Biopharma INC. | $185.16 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $164.69 | 2020-2021 | |
| Genzyme Corporation | $52.18 | 2022-2023 | |
| Pfizer INC. | $30.10 | 2023 | |
| Alfasigma USA, INC. | $23.23 | 2020 | |
| Merck Sharp & Dohme LLC | $19.46 | 2022 | |
| Braintree Laboratories, INC. | $14.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Jolley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.